| Population 2014 |
24 million |
| | |
| | | | | | | |
| Estimates of TB burden * 2014 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
13 |
(7.5–19) |
52 |
(31–79) |
| Mortality (HIV+TB only) |
3.5 |
(1.5–6.2) |
14 |
(6.2–26) |
| Prevalence (includes HIV+TB) |
120 |
(61–200) |
490 |
(251–807) |
| Incidence (includes HIV+TB) |
90 |
(58–130) |
370 |
(240–529) |
| Incidence (HIV+TB only) |
23 |
(14–34) |
95 |
(58–141) |
| |
|
|
|
|
| Case detection, all forms (%) |
60 |
(42–92) |
|
|
| | |
| | | | | | | |
| Estimates of MDR-TB burden * 2014 |
|
New |
|
Retreatment |
| % of TB cases with MDR-TB |
1.7 |
(0.3–3.1) |
17 |
(4.4–30) |
MDR-TB cases among notified pulmonary
TB cases |
800 |
(140–1 500) |
740 |
(190–1 300) |
| | |
| | | | | | | |
| TB case notifications 2014 |
New ** |
Relapse |
| Pulmonary, bacteriologically confirmed |
22 046 |
|
2 682 |
| Pulmonary, clinically diagnosed |
25 262 |
|
0 |
| Extrapulmonary |
3 562 |
|
0 |
| |
|
|
|
| Total new and relapse |
53 552 |
|
|
| Previously treated, excluding relapses |
1 654 |
|
|
| Total cases notified |
55 206 |
|
|
| | |
| | | | | | | |
| Among 22 046 new and relapse cases: | | | | | | |
| 909 (4%) cases aged under 15 years; male:female ratio: 1.4 | | | | |
| | | | | | | |
| Reported cases of RR-/MDR-TB 2014 |
New |
Retreatment |
Total ** |
| Cases tested for RR-/MDR-TB |
29 (<1%) |
214 (5%) |
243 |
| Laboratory-confirmed RR-/MDR-TB cases |
|
|
307 |
| Patients started on MDR-TB treatment *** |
|
|
307 |
| | |
| | | | | | | |
| TB/HIV 2014 |
Number |
(%) |
| TB patients with known HIV status |
27 699 |
(50) |
| HIV-positive TB patients |
2 827 |
(10) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |
2 827 |
(100) |
| HIV-positive TB patients on antiretroviral therapy (ART) |
|
|
| HIV-positive people screened for TB |
|
|
| HIV-positive people provided with IPT |
|
|
| | |
| | | | | | | |
| Treatment success rate and cohort size |
(%) |
Cohort |
| New and relapse cases registered in 2013 |
(23) |
60 807 |
| Previously treated cases, excluding relapse, registered in 2013 |
(39) |
6 844 |
| HIV-positive TB cases, all types, registered in 2013 |
|
24 445 |
| RR-/MDR-TB cases started on second-line treatment in 2012 |
|
0 |
| XDR-TB cases started on second-line treatment in 2012 |
|
0 |
| | |
| | | | | | | |
| Laboratories 2014 |
|
| Smear (per 100 000 population) |
0.4 |
| Culture (per 5 million population) |
0.4 |
| Drug susceptibility testing (per 5 million population) |
0.4 |
| Sites performing Xpert MTB/RIF |
1 |
| Is second-line drug susceptibility testing available? |
Yes, in country |
| | |
| | | | | | | |
| Financing TB control 2015 |
|
| National TB programme budget (US$ millions) |
24 |
| % Funded domestically |
30% |
| % Funded internationally |
13% |
| % Unfunded |
57% |
| | |
| | | | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** Includes cases with unknown previous TB treatment history | | | |
| *** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having | |
| RR-/MDR-TB | | | | | | | |
| | | | | | | |